Altimmune Inc (ALT)

04:21 AM

Altimmune Inc (ALT) Stock: A Year of Stock Market Dynamics - investchronicle.com

04:21 AM

12:49 PM

Lost Investment in Altimmune, Inc. (ALT)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire

12:49 PM

03:34 AM

Is Altimmune Inc. a good long term investmentPowerful growth strategies - Autocar Professional

03:34 AM

12:06 PM

What drives Altimmune Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

12:06 PM

Jul 22, 2025

What analysts say about Altimmune Inc. stockPowerful growth strategies - Autocar Professional

Jul 22, 2025

Jul 22, 2025

Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 22, 2025

Jul 22, 2025

Why Altimmune Inc. stock attracts strong analyst attentionRisk Adjusted Stock Signals - Newser

Jul 22, 2025

Jul 22, 2025

Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Fraud Investigation - ACCESS Newswire

Jul 22, 2025

Jul 21, 2025

Altimmune Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional

Jul 21, 2025

Jul 21, 2025

Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsALT - ACCESS Newswire

Jul 21, 2025

Jul 21, 2025

Investors in Altimmune, Inc. (ALT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - Newsfile

Jul 21, 2025

Jul 20, 2025

(ALT) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 20, 2025

Jul 20, 2025

ALT ALERT: Ongoing Investigation Into Altimmune, Inc.Contact Levi & Korsinsky - ACCESS Newswire

Jul 20, 2025

Jul 19, 2025

Securities Litigation as a Strategic Tool: Lessons from Altimmune's Legal Challenges and the Role of the Schall Law Firm - AInvest

Jul 19, 2025

Jul 19, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Jul 19, 2025

Jul 18, 2025

Did Altimmune, Inc. (ALT) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire

Jul 18, 2025

Jul 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News

Jul 17, 2025

Jul 15, 2025

What makes Altimmune Inc. stock price move sharplyFree Smart Money Stock Analysis - Newser

Jul 15, 2025

Jul 15, 2025

How Altimmune Inc. stock performs during market volatilityTrending Stock Alert - Newser

Jul 15, 2025

Jul 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.

Jul 14, 2025

Jul 14, 2025

OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jul 14, 2025

Jul 14, 2025

Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jul 14, 2025

Jul 13, 2025

Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World

Jul 13, 2025

Jul 12, 2025

Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World

Jul 12, 2025

Jul 12, 2025

Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest

Jul 12, 2025

Jul 12, 2025

Altimmune (NASDAQ:ALT) Rating Increased to Strong Sell at The Goldman Sachs Group - Defense World

Jul 12, 2025

Jul 12, 2025

The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World

Jul 12, 2025

Jul 12, 2025

Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World

Jul 12, 2025

Jul 12, 2025

JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World

Jul 12, 2025

Jul 11, 2025

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks

Jul 11, 2025

Jul 10, 2025

Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView

Jul 10, 2025

Jul 10, 2025

Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria

Jul 10, 2025

Jul 10, 2025

Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada

Jul 10, 2025

Jul 10, 2025

Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest

Jul 10, 2025

Jul 10, 2025

Altimmune resumed with a Sell at Goldman Sachs - TipRanks

Jul 10, 2025

Jul 10, 2025

Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks

Jul 10, 2025

Jul 10, 2025

Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 10, 2025

ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Jul 10, 2025

Jul 09, 2025

How To Trade (ALT) - news.stocktradersdaily.com

Jul 09, 2025